Sonja Ann Curtis, | |
525 Metro Pl N Ste 100, Dublin, OH 43017-5343 | |
(855) 289-1722 | |
Not Available |
Full Name | Sonja Ann Curtis |
---|---|
Gender | Female |
Speciality | Case Manager/care Coordinator |
Location | 525 Metro Pl N Ste 100, Dublin, Ohio |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093209553 | NPI | - | NPPES |
2910854 | Medicaid | OH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | LPN.160660.MEDS.IV (Ohio) | Secondary |
171M00000X | Case Manager/care Coordinator | (Ohio) | Primary |
Mailing Address | Practice Location Address |
---|---|
Sonja Ann Curtis, 525 Metro Pl N Ste 100, Dublin, OH 43017-5343 Ph: (855) 289-1722 | Sonja Ann Curtis, 525 Metro Pl N Ste 100, Dublin, OH 43017-5343 Ph: (855) 289-1722 |
News Archive
Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).
U.S. Global AIDS Coordinator Eric Goosby on Tuesday in an interview with Reuters discussed how as part of its new strategy PEPFAR will aim to "to transform healthcare in some of the world's poorest countries," the news agency writes.
Washington Research Foundation is helping University of Washington clinicians and researchers —one a MacArthur Fellow — to develop BiliCam, an iPhone app that can help determine the severity of jaundice in a newborn without having to draw blood.
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).
› Verified 7 days ago